Étude de phase III, multicentrique, à répartition aléatoire, à double insu et contrôlée par placebo comparant l’efficacité et l’innocuité de l’INAVOLISIB en combinaison avec PHESGO? à celles d’un placebo en combinaison avec PHESGO comme traitement d’entretien après un traitement d’induction de première intention chez des participants atteints d’un cancer du sein localement avancé ou métastatique HER2-POSITIF avec mutation du gène PIK3CA
WO44263/INAVO122
NCT05894239
 Recruiting
|
CIUSSS DU NORD-DE-L'ILE-DE-MONTREAL
HOPITAL DU SACRE-COEUR-DE-MONTREAL
|
Breast |
Dr. Isabelle Gingras
Marie-Anne Capobianco
514-338-2222 poste 3493
|
A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence
EMBER-4
NCT05514054
Recruiting
|
CIUSSS DU NORD-DE-L'ILE-DE-MONTREAL
HOPITAL DU SACRE-COEUR-DE-MONTREAL
|
Breast |
Dr. Isabelle Gingras
Marie-Anne Capobianco
514-338-2222 poste 3493
|
Un registre prospectif, observationnel et non interventionnel conçu pour faire état de l'incidence et de la prévalence de certains paramètres biologiques chez les patients atteints de LMC
Registre canadien LMC
Recruiting
|
CIUSSS DU NORD-DE-L'ILE-DE-MONTREAL
HOPITAL DU SACRE-COEUR-DE-MONTREAL
|
Chronic Myeloid Leukemia |
Dr. Inès Chamakhi
Caroline Chagnon
514-338-2222 poste 2816
|
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
CRC10 (NRG-GI008) (CIRCULATE-US)
NCT05174169
Recruiting
|
CIUSSS DU NORD-DE-L'ILE-DE-MONTREAL
HOPITAL DU SACRE-COEUR-DE-MONTREAL
|
Colon and Rectum |
Dr. Setareh Samimi
Maia Labelle
514-338-2222 poste 2818
|
A Comprehensive and Observational Myeloproliferative
Neoplasms (MPN) Registry in the Province of Quebec
Registre NMP
Recruiting
|
CIUSSS DU NORD-DE-L'ILE-DE-MONTREAL
HOPITAL DU SACRE-COEUR-DE-MONTREAL
|
MPN: Vaquez, Essential Thrombocytemia, Myeloid Metaplasia |
Dr. Inès Chamakhi
Caroline Chagnon
514-338-2222 poste 2816
|
A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma
SUCCESSOR-01/CA057-001
NCT05519085
Recruiting
|
CIUSSS DU NORD-DE-L'ILE-DE-MONTREAL
HOPITAL DU SACRE-COEUR-DE-MONTREAL
|
Myeloma |
Dr. Jean-Samuel Boudreault-Pedneault
Maia Labelle
514-338-2222 poste 2818
|
A Randomized, 2-Arm, Phase 3 Study of Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease-Positive After Undergoing Autologous Stem-Cell Transplantation
MagnetisMM-7 (C1071007)
NCT05317416
Recruiting
|
CIUSSS DU NORD-DE-L'ILE-DE-MONTREAL
HOPITAL DU SACRE-COEUR-DE-MONTREAL
|
Myeloma |
Dr. Jean-Samuel Boudreault-Pedneault
Marie-Anne Capobianco
514-338-2222 poste 3493
|
A phase 3, open-label study of elranatamab monotherapy versus elotuzumab, pomalidomide, dexamethasone (epd) or pomalidomide, bortezomib, dexamethasone (pvd) or carfilzomib, dexamethasone (kd) in participants with relapsed/refractory multiple myeloma who received prior anti-cd38 directed therapy
MagnetisMM-32 (C1071032)
NCT06152575
Recruiting
|
CIUSSS DU NORD-DE-L'ILE-DE-MONTREAL
HOPITAL DU SACRE-COEUR-DE-MONTREAL
|
Myeloma |
Dr. Jean-Samuel Boudreault-Pedneault
Maia Labelle
514-338-2222 poste 2818
|
A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression (TC ? 50%) and Without Actionable Genomic Alterations
TROPION-Lung10
NCT06357533
Recruiting
|
CIUSSS DU NORD-DE-L'ILE-DE-MONTREAL
HOPITAL DU SACRE-COEUR-DE-MONTREAL
|
Non Small Cells - Lung |
Dr. Kevin Jao
Caroline Chagnon
514-338-2222 poste 2816
|
A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C
CodeBreaK 202
NCT05920356
Recruiting
|
CIUSSS DU NORD-DE-L'ILE-DE-MONTREAL
HOPITAL DU SACRE-COEUR-DE-MONTREAL
|
Non Small Cells - Lung |
Dr. Kevin Jao
Maia Labelle
514-338-2222 poste 2818
|
Groupe d'étude en oncologie du Québec